Pityriasis Lichenoides Chronica, Role of Streptococcal Infection and Azithromycin
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Primary outcome:
The primary outcome at end of study (EOS) is to compare the therapeutic efficacy of
Azithromycin in the treatment of pityriasis lichenoides chronica (PLC) with that of a
well-documented line of therapy namely narrow band ultra violet B (nbUVB).
Secondary outcomes:
1. To identify the possibility of streptococcal throat infection as a possible underlying
etiology in PLC.